Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: radiolabeling, serum stability, and biodistribution and tumor uptake studies.
暂无分享,去创建一个
[1] Hyun A. Song,et al. Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy. , 2012, Bioconjugate chemistry.
[2] M. Brechbiel,et al. Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates. , 2011, Bioorganic & medicinal chemistry letters.
[3] M. Brechbiel,et al. Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications. , 2011, Bioconjugate chemistry.
[4] Xiang Ma,et al. Efficient synthesis and evaluation of bimodal ligand NETA. , 2008, Bioorganic & medicinal chemistry letters.
[5] K. Schwarz,et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells. , 2007, Cancer research.
[6] S. Kneifel,et al. Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P , 2006, Clinical Cancer Research.
[7] M. Brechbiel,et al. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy. , 2006, Nuclear medicine and biology.
[8] Yong Li,et al. Intralesional targeted alpha therapy for metastatic melanoma , 2005, Cancer biology & therapy.
[9] M. Brechbiel,et al. Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease , 2004, Clinical Cancer Research.
[10] M. Brechbiel,et al. Development of a spectroscopic assay for bifunctional ligand-protein conjugates based on copper. , 2004, Nuclear medicine and biology.
[11] M. Brechbiel,et al. Antibody-targeted radiation cancer therapy , 2004, Nature Reviews Drug Discovery.
[12] L. Chappell,et al. Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid for radiolabeling proteins. , 2003, Nuclear medicine and biology.
[13] J. Humm,et al. Targeted α particle immunotherapy for myeloid leukemia , 2002 .
[14] M. Brechbiel,et al. Synthesis and biological evaluation of novel macrocyclic ligands with pendent donor groups as potential yttrium chelators for radioimmunotherapy with improved complex formation kinetics. , 2002, Journal of medicinal chemistry.
[15] L. Chappell,et al. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.
[16] M. Brechbiel,et al. The Development of the α‐Particle Emitting Radionuclides 212Bi and 213Bi, and Their Decay Chain Related Radionuclides, for Therapeutic Applications , 2001 .
[17] M. Brechbiel,et al. The development of the alpha-particle emitting radionuclides 212Bi and 213Bi, and their decay chain related radionuclides, for therapeutic applications. , 2001, Chemical reviews.
[18] S. Mirzadeh,et al. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.
[19] R. Dillman,et al. Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update. , 2000, Seminars in oncology.
[20] P. Bunn,et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. , 2000, Seminars in oncology.
[21] Y. Erdi,et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] D. Scheinberg,et al. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] R. Finn,et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.
[24] Krishan Kumar,et al. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .